UTHR UNITED THERAPEUTICS Corp

Price (delayed)

$216.005

Market cap

$10B

P/E Ratio

13.52

Dividend/share

N/A

EPS

$15.98

Enterprise value

$9.84B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
UNITED THERAPEUTICS's net income has surged by 53% YoY and by 2.8% QoQ
The company's EPS has surged by 51% YoY and by 2.4% QoQ
The stock's P/E is 7% below its last 4 quarters average of 14.9 but 5% above its 5-year quarterly average of 13.2

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
46.3M
Market cap
$10B
Enterprise value
$9.84B
Valuations
Price to earnings (P/E)
13.52
Price to book (P/B)
2.05
Price to sales (P/S)
5.08
EV/EBIT
10.01
EV/EBITDA
9.51
EV/Sales
5.08
Earnings
Revenue
$1.94B
EBIT
$983M
EBITDA
$1.03B
Free cash flow
$663.7M
Per share
EPS
$15.98
Free cash flow per share
$14.59
Book value per share
$105.24
Revenue per share
$42.56
TBVPS
$131.87
Balance sheet
Total assets
$6.04B
Total liabilities
$1.25B
Debt
$800M
Equity
$4.8B
Working capital
$3.04B
Liquidity
Debt to equity
0.17
Current ratio
9.85
Quick ratio
8.91
Net debt/EBITDA
-0.16
Margins
EBITDA margin
53.4%
Gross margin
92.2%
Net margin
37.6%
Operating margin
50.6%
Efficiency
Return on assets
12.8%
Return on equity
16.3%
Return on invested capital
18.8%
Return on capital employed
17.2%
Return on sales
50.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-2.84%
1 week
-0.69%
1 month
-11.38%
1 year
20.45%
YTD
-22.33%
QTD
-22.33%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$1.94B
Gross profit
$1.78B
Operating income
$979.7M
Net income
$727.3M
Gross margin
92.2%
Net margin
37.6%
The operating income has soared by 76% YoY
The company's operating margin has surged by 53% YoY but it fell by 3.4% QoQ
UNITED THERAPEUTICS's net income has surged by 53% YoY and by 2.8% QoQ
The net margin has grown by 33% YoY

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
P/E
13.52
P/B
2.05
P/S
5.08
EV/EBIT
10.01
EV/EBITDA
9.51
EV/Sales
5.08
The company's EPS has surged by 51% YoY and by 2.4% QoQ
The stock's P/E is 7% below its last 4 quarters average of 14.9 but 5% above its 5-year quarterly average of 13.2
The equity has increased by 21% year-on-year and by 5% since the previous quarter
UTHR's price to book (P/B) is 11% higher than its 5-year quarterly average of 1.9 but 8% lower than its last 4 quarters average of 2.3
The stock's P/S is 31% above its 5-year quarterly average of 4.0 but 7% below its last 4 quarters average of 5.6
The company's revenue rose by 15% YoY and by 4.1% QoQ

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The company's return on sales rose by 40% YoY
The ROIC has grown by 37% YoY
UNITED THERAPEUTICS's return on assets has increased by 32% YoY
The ROE has grown by 27% YoY

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The current ratio has grown by 29% YoY
The quick ratio has increased by 28% year-on-year
The debt is 83% less than the equity
The equity has increased by 21% year-on-year and by 5% since the previous quarter
UNITED THERAPEUTICS's debt to equity has decreased by 15% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.